Laboratory Biomarker Analysis for Cardiotoxicity
Phase-Based Progress Estimates
Effectiveness
Safety
Cardiotoxicity+6 More
Laboratory Biomarker Analysis - OtherEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial studies the effects of carvedilol on preventing heart problems in patients with HER2-positive breast cancer.
Eligible Conditions
- Cardiotoxicity
- Malignant neoplasm of breast
- Breast
- ERBB2 gene
- Brain
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: Up to 108 weeks
Up to 108 weeks
Drug adherence
Incidence of adverse events associated with beta blocker treatment
Rate of death
Rate of first interruption of trastuzumab
Time to first occurrence of cardiac event
Time to the first identification of cardiac dysfunction
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Trial Design
3 Treatment Groups
Arm III (observation)
1 of 3
Arm II (no intervention)
1 of 3
Arm I (carvedilol)
1 of 3
Active Control
Experimental Treatment
817 Total Participants · 3 Treatment Groups
Primary Treatment: Laboratory Biomarker Analysis · No Placebo Group · Phase 3
Arm I (carvedilol)Experimental Group · 2 Interventions: Laboratory Biomarker Analysis, Carvedilol · Intervention Types: Other, Drug
Arm III (observation)ActiveComparator Group · 2 Interventions: Laboratory Biomarker Analysis, Patient Observation · Intervention Types: Other, Other
Arm II (no intervention)
Other
ActiveComparator Group · 1 Intervention: Laboratory Biomarker Analysis · Intervention Types: OtherTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carvedilol
FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 108 weeks
Who is running the clinical trial?
Southwest Oncology GroupLead Sponsor
382 Previous Clinical Trials
258,897 Total Patients Enrolled
1 Trials studying Cardiotoxicity
180 Patients Enrolled for Cardiotoxicity
National Cancer Institute (NCI)NIH
12,990 Previous Clinical Trials
41,296,821 Total Patients Enrolled
18 Trials studying Cardiotoxicity
3,166 Patients Enrolled for Cardiotoxicity
Justin FloydPrincipal InvestigatorSouthwest Oncology Group
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have had previous anthracycline exposure.
You have completed the registration form.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments